Get the Stockscreener App
5.19
2.81%
-0.15
After Hours:
5.19
Immuneering Corp stock is traded at $5.19, with a volume of 1.06M.
It is down -2.81% in the last 24 hours and down -3.89% over the past month.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
See More
Previous Close:
$5.34
Open:
$5.4
24h Volume:
1.06M
Relative Volume:
1.18
Market Cap:
$335.78M
Revenue:
$500
Net Income/Loss:
$-56.02M
P/E Ratio:
-3.7579
EPS:
-1.3811
Net Cash Flow:
$-45.49M
1W Performance:
-1.14%
1M Performance:
-3.89%
6M Performance:
-21.60%
1Y Performance:
+336.13%
1-Day Range:
$5.06
$5.40
1-Week Range:
$5.06
$5.53
52-Week Range:
$1.10
$10.08
Immuneering Corp Stock (IMRX) Company Profile
Name
Immuneering Corp
Sector
Industry
Phone
617-500-8080
Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
5.19 | 345.48M | 500 | -56.02M | -45.49M | -1.3811 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Initiated | Leerink Partners | Outperform |
| Dec-13-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Mar-15-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-15-24 | Reiterated | Needham | Buy |
| Mar-15-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-01-23 | Initiated | Needham | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-19-23 | Upgrade | Mizuho | Neutral → Buy |
| Apr-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-30-23 | Initiated | Mizuho | Neutral |
| Feb-03-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-08-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-01-22 | Initiated | Oppenheimer | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
View All
Immuneering Corp Stock (IMRX) Latest News
We're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash Wisely - Yahoo Finance
Insider Buyers At Immuneering Sitting On US$361k Profit - Sahm
Immuneering Corp (IMRX) Stock Price, Quote, News & History - Benzinga
Immuneering brings 55-patient pancreatic survival update to ASCO oral - Stock Titan
Immuneering (IMRX) details 2026 virtual meeting, director votes and auditor ratification - Stock Titan
Immuneering (IMRX) Reveals Promising Genetic Data at Upcoming AA - GuruFocus
Immuneering presents genetic data on atebimetinib resistance - Investing.com
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond - The Manila Times
In 123 patients, Immuneering's cancer drug showed rare resistance signals - Stock Titan
Immuneering Corporation (IMRX) Stock: Technical Strength Check (Risk Aversion) 2026-04-18Hedge Fund Favorites - Newser
Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears - Yahoo Finance
Immuneering (NASDAQ:IMRX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Needham healthcare fireside chat adds Immuneering CEO on April 13 - Stock Titan
Immuneering CorporationClass A Common Stock (NQ: IMRX - The Chronicle-Journal
Immuneering Corp Stock: Precision Oncology Innovator with Deep Pipeline Potential for North American - AD HOC NEWS
Bull Bear: Can Immuneering Corporation scale operations efficiently2026 Buyback Activity & Daily Volume Surge Signals - baoquankhu1.vn
Immuneering Corp Stock (ISIN: US45255L1089) Faces Short-Term Pressure Amid Clinical Momentum and Ana - AD HOC NEWS
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival - The Manila Times
Immuneering Corp (IMRX) CPO acquires shares through employee stock plan - Stock Titan
New MEK approach in 64 cancer patients shows fewer resistance mutations - Stock Titan
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - AOL.com
Immuneering (IMRX) to Release Earnings on Thursday - MarketBeat
Piper Sandler cuts Immuneering stock price target on launch timing - Investing.com
Why Immuneering Corporation stock could outperform in 2026Earnings Growth Report & Community Supported Trade Ideas - Naître et grandir
Immuneering (NASDAQ:IMRX) Raised to Hold at Wall Street Zen - MarketBeat
Immuneering Corporation Q4 & Full Year 2025 Earnings: EPS Beats -$0.18 Estimate - Bayelsa Watch
Oppenheimer reiterates Immuneering stock rating on pipeline progress - Investing.com
Immuneering 2025 10-K: $0 Revenue, $(1.27) EPS and $(56.0)M Net Loss - TradingView
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - The Manila Times
Immuneering Corporation Reports 64% Overall Survival in Phase 2a Trial for First-Line Pancreatic Cancer and Outlines 2026 Development Plans - Quiver Quantitative
Immuneering to Present at the Leerink Global Healthcare Conference - The Manila Times
Late-stage cancer firm Immuneering to outline pipeline at Miami investor event - Stock Titan
IMRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3 - Yahoo Finance
IMRX Should I Buy - Intellectia AI
Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Merger Talk: Does Immuneering Corporation outperform in volatile marketsJuly 2025 Market Mood & Reliable Volume Spike Alerts - baoquankhu1.vn
Investment Report: Does Immuneering Corporation meet Warren Buffetts criteriaPortfolio Update Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - The Manila Times
Immuneering Corporation to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Quiver Quantitative
Oncology company Immuneering to detail pipeline, strategy at virtual Oppenheimer event - Stock Titan
Sanofi Invests $18.96 Million in Immuneering Corporation $IMRX - MarketBeat
Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
What is Immuneering Corporation’s valuation compared to sector2025 Performance Recap & Long-Term Safe Investment Plans - mfd.ru
Empery Asset Management, LP Reduces Stake in Immuneering Corp - GuruFocus
Thomas Schall Buys 21,645 Shares of Immuneering (NASDAQ:IMRX) Stock - Defense World
Immuneering (NASDAQ:IMRX) Insider Harold Eugene Brakewood Purchases 5,250 Shares of Stock - MarketBeat
Immuneering’s (IMRX) chief business officer buys $24,990 in stock By Investing.com - Investing.com Australia
Immuneering Corp Stock (IMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):